View Older Stories View More Recent Stories
-
RGS Energy Completes $2.8 Million Public Offering of Preferred Stock and Warrants
-
Roth Capital Positive on Heat Biologics (HTBX) as HS-110 Combo Phase 1b Enrollment Resumes
-
Callidus Software, Inc. (CALD) to Offer 4M Common Shares
-
CallidusCloud Announces Proposed Follow-On Offering
-
Roth Capital Affirms Ligand Pharma (LGND) at 'Buy' Following Initiation of LGD-6972 Phase 2 in T2D
-
B. Riley & Co. Promotes Head of Capital Markets Andy Moore to President
-
Roth Capital Downgrades Applied Genetic Technologies Corp. (AGTC) to Neutral
-
Roth Capital Affirms Bioblast Pharma (ORPN) at 'Buy'; Extension Study Data Shows Sustainable Improvements
-
Roth Remains Neutral on Peregrine Pharma (PPHM); Pipeline Advancing Well, but Catalysts Remain
-
RGS Energy (RGSE) Prices Unit Offering for Proceeds of ~$2.2M
-
RGS Energy Announces Pricing of Unit Offering
-
Roth Positive on BioLineRx (BLRX) Amid Latest BL-8040 Phase 2a Data in r/r AML
-
Buy Palatin Technologies (PTN) Ahead of Phase 3 BMT Data - Roth Capital
-
Medigus (MDGS) Prices 1.28M Registered Direct Offering at $1.15/ADS
-
Medigus Announces Pricing of $1.47 Million Registered Direct Offering
-
Streetinsider.com's Hot Lunchtime Reads 9/7: (AMD) (LGND) (EXPR) (GILD)
-
Roth Capital Upgrades Cogentix Medical (CGNT) to Buy
-
Roth Capital Bumps PT on Ligand Pharma (LGND) up to $151 Following Sparsentan Data; Affirms at 'Buy'
-
Inphi Corp. (IPHI) Announces Pricing of Increased Conv. Senior Notes Offering
-
Inphi Corporation Prices Offering of $250.0 Million of Convertible Senior Notes
-
Superior Drilling Products (SDPI) to Offer 5M Common Shares
-
Superior Drilling Products, Inc. Launches Common Stock Offering
-
Roth Capital Positive on Ligand Pharma (LGND) Ahead of Sept. Catalysts; Affirms at 'Buy'
-
Roth Capital Sees Relatively Flat Q3 for FuelCell (FCEL), But Says Co. Still has Robust Pipeline
-
Roth Capital Downgrades Interactive Intelligence (ININ) to Neutral
-
Notable Analyst Rating Changes 9/1: (JCP) (BSX) (WEX) Upgraded; (PNR) (ISIL) Downgraded
-
Ideal Power to Participate at Upcoming Investor Conferences
-
Roth Capital Starts Cypress Semi (CY) at Buy
-
Roth Capital Assumes Intel (INTC) at Buy
-
Roth Capital Assumes InvenSense (INVN) at Buy
-
Roth Capital Assumes QuickLogic (QUIK) at Buy
-
Roth Capital Starts Rambus Inc. (RMBS) at Buy
-
Roth Capital Starts DSP Group (DSPG) at Buy
-
Roth Capital Starts Applied Micro Circuits (AMCC) at Buy
-
Roth Capital Assumes Adesto Technologies (IOTS) at Buy
-
ROTH Capital Partners to Host Solar & Storage Symposium at Solar Power International
-
Lucas Energy Closes Acquisition Transaction And Related Financings
-
Lucas Energy Closes Acquisition Transaction And Related Financings
-
Notable Analyst Rating Changes 8/29: (CBL) (ATI) (KS) Upgraded; (HAYN) (KEY) (SQ) Downgraded
-
UPDATE: Roth Capital Starts Neuralstem (CUR) at Buy
-
Form X-17A-5 ROTH CAPITAL PARTNERS, For: Jun 30
-
MaxLinear, Inc. to Present at Upcoming Financial Conferences
-
Emerging Solar Markets Remain Key for JinkoSolar (JKS); Roth Capital Affirms at 'Neutral'
-
Roth Capital Affirms BioBlast Pharma (ORPN) at 'Buy'; Sees Trehalose Plan Heading in Right Direction
-
Notable Analyst Rating Changes 8/25: (LLL) (RIG) (NFLX) Upgraded; (S) (OZM) (DDR) Downgraded
-
Roth Capital Keeps Prima BioMed (PBMD) at 'Buy' Following Receipt of IMP731-Related European Patent
-
ROTH Capital Partners to Host Datacenter Technology Corporate Access Day in San Francisco, Calif. on September 7, 2016
-
Roth Capital Downgrades PCM, Inc (PCMI) to Neutral
-
Roth Sees Lion Biotech's (LBIO) NCI Announcement as Important Given Impact on Thesis; Affirms at 'Buy'
-
Roth Capital Starts Actinium Pharma (ATNM) at Buy, PT $5
